Cetrelimab
- Generic Name
- Cetrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050478-92-5
- Unique Ingredient Identifier
- LYK98WP91F
- Background
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
- Associated Conditions
- -
- Associated Therapies
- -
CD8 PET Imaging in Metastatic Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT06534190
- Locations
- 🇳🇱
VUMC, Amsterdam, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇬🇧University of Cambridge, Cambridge, United Kingdom
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06311578
- Locations
- 🇪🇸
Hosp Univ Vall D Hebron, Barcelona, Spain
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06116786
- Locations
- 🇺🇸
Next Virginia, Fairfax, Virginia, United States
🇩🇪Charite Research Organisation GmbH, Berlin, Germany
🇩🇪Universitaetsklinikum Giessen und Marburg GmbH, Giessen, Germany
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT05908734
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇲🇾University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇧🇷Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Brazil
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1135
- Registration Number
- NCT05714202
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇧🇷Liga Paranaense de Combate ao Cancer, Curitiba, Brazil
🇧🇷Hospital Regional do Cancer - Hospital de Esperança, Presidente Prudente, Brazil
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05242445
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
🇪🇸Hosp. Gral. Univ. Valencia, Valencia, Spain
🇵🇱PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p., Gdansk, Poland
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04919512
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
🇺🇸UAMS Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 518
- Registration Number
- NCT04658862
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇦🇷Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina
🇧🇷Fundacao Pio XII, Barretos, Brazil
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT04640623
- Locations
- 🇺🇸
Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Genesis Healthcare Partners - Genesis Research Greater Los Angeles, Sherman Oaks, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.